Traszeptin (Trastuzumab) 440 mg Injection

Traszeptin is a trastuzumab 440 mg lyophilised powder for solution for intravenous infusion, manufactured by PharmEvo. Trastuzumab is a monoclonal antibody that selectively targets the HER2 (human epidermal growth factor receptor 2) protein, used in the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric or gastro-oesophageal junction adenocarcinoma.

⚠ Prescription required. This is a prescription-only medicine. A valid prescription from a registered oncologist must be verified before dispensing. Administered under medical supervision in a clinical setting only.

• Active ingredient: Trastuzumab
• Strength: 440 mg per vial
• Form: Lyophilised powder for IV infusion (reconstituted before use)
• Manufacturer: PharmEvo
• Pricing is per vial
• Cold-chain storage at 2–8 °C; do not freeze

Dosage and administration are determined by the treating oncologist. This listing is informational and does not replace professional medical advice. Consult your specialist before use.